- Q1 2024 OncoCyte Corp Earnings Call TranscriptMay 15, 2024$2.88Earnings
- Q4 2023 OncoCyte Corp Earnings Call TranscriptApr 12, 2024$4.96 (+62.09%)Earnings
- Q3 2023 OncoCyte Corp Earnings Call TranscriptNov 09, 2023$2.55 (+10.15%)Earnings
- Q2 2023 OncoCyte Corp Earnings Call TranscriptAug 10, 2023$3.85Earnings
- OncoCyte Corp Extraordinary Shareholders Meeting TranscriptJul 24, 2023
- OncoCyte Corp Annual Shareholders Meeting TranscriptJun 23, 2023
- Q1 2023 OncoCyte Corp Earnings Call TranscriptMay 11, 2023$5.28Earnings
- Q4 2022 OncoCyte Corp Earnings Call TranscriptApr 03, 2023$5.2Earnings
- Q3 2022 OncoCyte Corp Earnings Call TranscriptNov 10, 2022$13.56Earnings
- OncoCyte Corp at UBS Genomics 2.0 and MedTech Innovations Summit TranscriptAug 11, 2022
- Q2 2022 OncoCyte Corp Earnings Call TranscriptAug 10, 2022$17.17 (-5.39%)Earnings
- OncoCyte Corp DetermalO™ and Tumor Microenvironment in Clinical Practice Key Opinion Leader TranscriptJun 28, 2022
- Q1 2022 OncoCyte Corp Earnings Call TranscriptMay 11, 2022$22.8Earnings
- Q4 2021 OncoCyte Corp Earnings Call TranscriptMar 10, 2022$34.4Earnings
- OncoCyte Corp to Discuss Development and Co-Marketing Agreement with Thermo Fisher Scientific Inc Call TranscriptJan 18, 2022
- OncoCyte Corp Investor and Analyst Day TranscriptDec 14, 2021
- Q3 2021 OncoCyte Corp Earnings Call TranscriptNov 09, 2021$69.9 (+2.75%)Earnings
- OncoCyte Corp Key Opinion Leader Presentation Part 2: DetermaIO™ in Triple-Negative Breast Cancer TranscriptSep 28, 2021
- OncoCyte Corp Key Opinion Leader Presentation Part 1: Transplant Rejection Testing TranscriptSep 22, 2021
- Q2 2021 OncoCyte Corp Earnings Call TranscriptAug 10, 2021$102Earnings
- OncoCyte Corp Annual Shareholders Meeting TranscriptJun 24, 2021
- Q1 2021 OncoCyte Corp Earnings Call TranscriptMay 17, 2021$79.4Earnings
- OncoCyte Corp DetermaIO™ Data KOL Webinar TranscriptApr 19, 2021
- Q4 2020 OncoCyte Corp Earnings Call TranscriptMar 16, 2021$96.76 (-0.04%)Earnings
- Q3 2020 OncoCyte Corp Earnings Call TranscriptNov 12, 2020$26.2Earnings
- OncoCyte Corp - EGFR And Molecular Risk Stratification In Early-Stage NSCLC TranscriptOct 22, 2020
- OncoCyte Corporation - Special Call TranscriptAug 19, 2020
- Q2 2020 OncoCyte Corp Earnings Call TranscriptJul 29, 2020$26.2Earnings
- OncoCyte Corp Announces Completion Of Determadx™ Clinical Validation Study TranscriptJun 29, 2020
- OncoCyte Corp Annual Shareholders Meeting TranscriptJun 17, 2020
- Q1 2020 OncoCyte Corp Earnings Call TranscriptMay 12, 2020$46.56Earnings
- Q4 2019 OncoCyte Corp Earnings Call TranscriptMar 25, 2020$46.56Earnings
- OncoCyte Corp to Acquire Insight Genetics Inc - Conference Call TranscriptJan 10, 2020
- Q3 2019 OncoCyte Corp Earnings Call TranscriptNov 14, 2019$40Earnings
- Q2 2019 OncoCyte Corp Earnings Call TranscriptAug 14, 2019$40Earnings
OncoCyte Corporation - Special Call Transcript
Hello, and welcome to today's webinar. My name is Sara Riordan. I'm a genetic counselor and the Director of Medical Education at Oncocyte. I'm very excited about what we are going to discuss today, which is a novel gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. This webinar is being recorded, and we will make the recording available after the webinar.
Now I'd like to introduce our 2 speakers. Dr. Naoto Ueno is a tenured professor in the Breast Medical Oncology Department of MD Anderson Cancer Center, Executive Director of the Morgan Welch Inflammatory Breast Cancer Program and Clinic, and Section Chief of Translational Breast Cancer Research in the Breast Medical Oncology Department. His research focuses on inflammatory breast cancer, triple-negative breast cancer and metastatic breast cancer. Having over 6 ongoing investigator-initiated clinical trials for patients with IBC, TNBC and bone metastasis. He supervises medical and graduate students, postdoctoral fellows, junior
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)